Does Rallies show Form 4 insider transactions for SPRB?

Yes. Rallies tracks SPRB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is SPRB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SPRB. It does not provide personalized investment advice.

SPRB (Spruce Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Spruce Biosciences, Inc. Common Stock (SPRB) is a publicly traded the market company. As of May 21, 2026, SPRB trades at $52.56 with a market cap of $138.92M and a P/E ratio of -1.02. SPRB moved +7.09% today. Year to date, SPRB is -37.27%; over the trailing twelve months it is +429.99%. Its 52-week range spans $4.28 to $240.00. Analyst consensus is strong buy with an average price target of $178.60. Rallies surfaces SPRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading SPRB stock inside the company?

Recent SPRB insider activity includes Parkman Healthcare Partners LLC bought 256, Parkman Healthcare Partners LLC sold 232, Parkman Healthcare Partners LLC sold 25, Parkman Healthcare Partners LLC bought 256, and Parkman Healthcare Partners LLC sold 232. Rallies tracks insider transaction dates, shares, prices, and estimated values.

SPRB Key Metrics

Key financial metrics for SPRB
Metric	Value
Price	$52.56
Market Cap	$138.92M
P/E Ratio	-1.02
EPS	$-50.83
Dividend Yield	0.00%
52-Week High	$240.00
52-Week Low	$4.28
Volume	34
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-38.97M
Gross Margin	0.00%

Recent SPRB Insider Trades

Parkman Healthcare Partners LLC bought 256 (~$4.59K) on Oct 6, 2025.
Parkman Healthcare Partners LLC sold 232 (~$4.48K) on Oct 6, 2025.
Parkman Healthcare Partners LLC sold 25 (~$436.393) on Oct 6, 2025.
Parkman Healthcare Partners LLC bought 256 (~$4.59K) on Oct 6, 2025.
Parkman Healthcare Partners LLC sold 232 (~$4.48K) on Oct 6, 2025.

Latest SPRB News

Spruce Biosciences Stock Drops 26% After 1.15M-Share $50 Offering — Apr 21, 2026
Spruce Biosciences Plans Q4 2026 BLA Submission, Secures $50M Loan Facility — Mar 9, 2026

SPRB Analyst Consensus

5 analysts cover SPRB: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $178.60.

Common questions about SPRB

Who is trading SPRB stock inside the company?: Recent SPRB insider activity includes Parkman Healthcare Partners LLC bought 256, Parkman Healthcare Partners LLC sold 232, Parkman Healthcare Partners LLC sold 25, Parkman Healthcare Partners LLC bought 256, and Parkman Healthcare Partners LLC sold 232. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for SPRB?: Yes. Rallies tracks SPRB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is SPRB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SPRB. It does not provide personalized investment advice.